-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Oncotelic Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2019 to 2023.
- Oncotelic Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$90.9K, a 442% decline year-over-year.
- Oncotelic Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$1.3M, a 22.1% increase year-over-year.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$1.56M, a 111% decline from 2022.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $14.4M.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.39M, a 41.7% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)